Project Grant HT94252310575
Award Date
8/15/23
Completion Date
8/14/25
Dollars Obligated
$617K
Federal Agency
Defense Health Agency
Federal Grant Program
12.420
Assistance Type
Project Grant
Place of Performance
Seattle, WA 98195, USA
Similar Awards
The Department of Defense's Military Medical Research and Development program (CFDA 12.420) has awarded a $1,708,955 project grant to the University of Washington to support a 3-year research study on "Enhanced Gene Therapy for DMD Using Larger Dystrophins and Lower Vector Doses". The grant, which commenced on September 15, 2023 and will be completed by September 14, 2026, aims to advance gene therapy approaches for the treatment of Duchenne muscular dystrophy (DMD). The University...
This Project Grant award from the Department of Defense's Military Medical Research and Development program (CFDA 12.420) provides $572,306 in funding to the University of Washington for a 3-year research project to develop "ENHANCED GENE THERAPY FOR DMD USING LARGER DYSTROPHINS AND LOWER VECTOR DOSES". The aim is to advance gene therapy approaches for treating Duchenne muscular dystrophy (DMD) by utilizing larger dystrophin gene constructs and reducing the required vector doses. The...
The University of Washington was awarded a $1,810,550 Project Grant from the Defense Health Agency under the Military Medical Research and Development federal grant program (CFDA 12.420). The grant will fund research from September 1, 2023 through September 30, 2026 to investigate early chemodenervation of the detrusor muscle to preserve bladder compliance and function over the long term following spinal cord injury. The Military Medical Research and Development program supports basic,...
The University of Washington will receive $749,915 from the Defense Health Agency through September 2023 to August 2027 under the Military Medical Research and Development federal grant program (CFDA 12.420). The funding will support the university's project to enhance the efficacy of androgen receptor antagonist therapy with tumor necrosis factor-alpha blockade in metastatic prostate cancer. The Military Medical Research and Development program aims to transform military and public health...
The federal Project Grant award of $932,918 from the Defense Health Agency's Military Medical Research and Development program (CFDA 12.420) is supporting research at the University of Washington to determine the role of somatic mosaicism in ovarian cancer predisposition. The grant, awarded on September 30, 2024 with an ultimate completion date of September 29, 2028, will enable the University of Washington to conduct innovative scientific studies to improve health outcomes for military...
This Project Grant award for $699,750 from the Defense Health Agency's Military Medical Research and Development program (CFDA 12.420) to the University of Washington aims to support the discovery and characterization of tissue-specific regulatory mutations that predispose to ovarian cancer. The award will fund research activities over a 3-year period from April 2024 to March 2027. As a leading research university, the University of Washington has extensive experience managing federal grants and...
The University of Washington received a $622,000 Project Grant from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) to conduct research on the fibrolamellar carcinoma tumor microenvironment using human tumor slice cultures. The award has a performance period from July 1, 2024 to June 30, 2026. Through this funding, the University of Washington will investigate innovative approaches to improve understanding of the fibrolamellar carcinoma tumor...
The U.S. Defense Health Agency awarded a $1,965,204 Project Grant under the Military Medical Research and Development program (CFDA 12.420) to the University of Washington to support the early-stage development of an anti-inflammatory melanocortin fusion protein for tactical combat casualty care. The award period runs from August 1, 2024 to July 31, 2027. This research aims to investigate new therapeutic approaches for improving health outcomes for military service members. As a prominent...
This Project Grant award, valued at $543,285.00, was provided by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) federal grant program. The award supports advanced biomedical research aimed at transforming healthcare for military service members, veterans, and the broader public. Specifically, the University of Washington will conduct research to develop new FDA-approved combination therapies for transforming the treatment of rhabdomyosarcoma, a rare...
The University of Washington was awarded a $1,137,371 project grant from the Department of the Army Medical Command under the Military Medical Research and Development federal grant program (CFDA 12.420). The grant will fund research from January 2021 through January 2025 to rapidly test a novel therapeutic strategy for COVID-19 using human organoids and blood vessel structures. The Military Medical Research and Development program aims to transform health care for service members and the public...